October 2023 — Monthly Briefing¶
1. What was read¶
702 research articles from 32 of the 33 journals on the roster.
A further 239 records (25% of the 941 this month's harvest returned) carry no abstract and are not research: news, correspondence, editor highlights and obituaries. PubMed types them Journal Article and nothing else, so the publication-type filter cannot see them — across the whole index they are 22.7% of it and 35% of general, and 3,801 of them are JAMA. Every count below is over the full harvest and is inflated by this; the figure above is not.
| General | Cancer | Immune | Bioinfo | Sysbio |
|---|---|---|---|---|
| 451 | 145 | 71 | 260 | 14 |
Volume swing against the median month: sysbio -42%
Check the source before reading anything into this. Two benign causes account for most of these. bioinfo every January carries the Nucleic Acids Research database issue and runs high. And several journals simply deposit nothing in some months: across the 44 months read, 4 of 33 journals are absent from at least one, worst being Nat Mach Intell (20 months missing, 81 papers in total) and Bioinformatics (4 months missing, 2,905 papers in total). This month is missing Nat Mach Intell. Queried directly, PubMed returns zero for those journal-months too — the holes are in the source, reproduced exactly by re-running the harvest. So a swing here is not evidence that a field went quiet, and is not usually evidence that the pipeline broke either.
Largest contributors: Nature 101, Science 96, Nucleic Acids Res 90, JAMA 89, Lancet 56, Bioinformatics 51.
2. Net change on the thread curve¶
| Thread | This month | Cumulative | Status |
|---|---|---|---|
cell-therapy |
+2 / −2 | +73 / −21 | forming |
ctdna-mrd |
+3 / −2 | +21 / −12 | splitting |
foundation-models |
+4 / −3 | +28 / −15 | splitting forming → splitting |
immunotherapy-resistance |
+10 / −4 | +90 / −27 | forming |
interception |
+2 / −2 | +53 / −7 | forming |
method-credibility |
+1 / −18 | +2 / −113 | crisis |
neoantigen-vaccines |
+4 / −1 | +32 / −13 | forming |
neuro-immune-microbiome-axis |
+6 / −1 | +53 / −5 | forming |
next-gen-checkpoints |
+2 / −2 | +16 / −14 | splitting |
single-cell-3d-genome |
+2 | +20 / −6 | forming |
suppressive-population-inversion |
−1 | +22 / −23 | contested splitting → contested |
Status is derived by rule, not asserted. Fewer than 5 cards → too-early; then refutes ≥ 2×supports → crisis; refutes > supports → contested; supports ≥ 2×refutes → forming; else splitting.
3. The evidence that moved it¶
Four separate neurotransmitter systems are attached to tumour control in one month, by four groups. A Nature paper puts the β1-adrenergic receptor between sympathetic innervation and CD8 T cell exhaustion (37731001); Nature Cancer describes T lymphocytes running a cholinergic programme of their own in liver cancer (37640929) and, separately, a designer peptide against a potassium channel at the cancer-cell–neuron interface in glioblastoma (37697045); Cancer Discovery ties GABA and electrical excitability to tumour initiation in melanoma (37553760). Noradrenaline, acetylcholine and GABA are three different chemistries, and melanoma is not a neural tumour, so this is not one finding reported four ways. Nature also has C. difficile acting on neurons and pericytes to drive neurogenic inflammation (37699522), which is the microbial arm arriving at the same cell type from the other side.
Immunotherapy resistance moves into the host's acute-phase response, twice in one journal. The Journal for ImmunoTherapy of Cancer carries C-reactive protein impairing CD8 T cells through a defined receptor-kinase axis in myeloma (37844994) and, in the same issue, IL-6/CRP elevation tracking with adenosine-pathway upregulation as a resistance marker in lung cancer (37852738). Two groups reach a circulating inflammatory protein from different diseases and different mechanisms. Cancer Cell supplies a mechanism rather than a correlation for the microbiome side, routing a microbiota effect on checkpoint response through HLA class I on the tumour cell (37738976).
Circulating tumour DNA is used as a trial's adaptation rule, not as its endpoint. Nature Medicine reports a phase 2 study in lung cancer in which the ctDNA response after pembrolizumab decides what happens next (37814061). The ctdna-mrd thread claims the analyte guides treatment rather than merely forecasting it, and a design in which the assay is wired into the protocol is the form of evidence that distinguishes the two; a prognostic association, however strong, is not.
Interception gets a long precursor window. Blood detects the genetic drivers of chronic lymphocytic leukaemia as much as sixteen years before diagnosis (37523714), which makes the pre-disease state a sampleable object over a period long enough to intervene in.
Corrected 2026-08-27
This paragraph also claimed a treated population, reading the Lynch syndrome
study (37845474) as immunotherapy given to people at risk rather
than to people with disease. The abstract says the cohort is 172
cancer-affected patients with Lynch syndrome who had already received
checkpoint blockade, and that the rate of tumour development was unchanged.
Both the population and the sign were wrong; the card is now refutes and
the paper is discussed under section 4(a).
Two platform results worth separating from their fields. Science has engineered bacteria colonising tumours and supplying the targeting signal for CAR T cells (37824640), which converts the microbiome from a modifier of therapy into a component of one and is the clearest solid-tumour cell-therapy idea in the month. And Science delivers per-cell-type DNA methylation together with chromatin conformation in human brain tissue (37824674), with a single-cell long-read concatemer method for higher-order structure in Nature Methods alongside it (37640936) — the assay behaving like a routine modality rather than a demonstration, which is what single-cell-3d-genome actually claims.
4. Refutations¶
(a) Landing on a tracked thread¶
The month's sharpest result is that two independent groups find tumour-genomic markers of immunogenicity insufficient. Nature Genetics reports that mismatch-repair deficiency does not by itself elicit tumour immunogenicity (37709863), and Cancer Cell reports immune resistance in an autochthonous lung model with high mutational burden, driven by p53 loss and clonal heterogeneity (37774698). Both strain immunotherapy-resistance from a direction its claim does not allow for: the claim is that resistance is being explained outside the tumour cell, and these two locate it firmly inside one, in the two genomic features most widely used to predict the opposite.
Nature Medicine measures what checkpoint blockade does to the neoplasia risk of Lynch syndrome patients who already have cancer, and the answer is nothing (37845474). Among 172 such patients, 21 (12%) developed a subsequent malignancy after exposure, 29 of 32 of those tumours were mismatch-repair deficient, and 24 of the 61 who went on to surveillance colonoscopy still had premalignant polyps; within matched pre- and post-exposure windows the overall rate of tumour development was unchanged. The authors' own conclusion is that Lynch-specific surveillance must continue. interception claims that the pre-malignant state can be acted on; the one drug class that clears established mismatch-repair-deficient tumours does not clear the lesions that precede them, in the patients most likely to form new ones.
Blood documents neurologic toxicity after BCMA-directed CAR T cells (37471607), in the indication where the platform has travelled furthest from CD19 — so the generalisation cell-therapy claims arrives carrying a toxicity bill, not free. And Nature Medicine argues that general-purpose conversational models used clinically require regulatory approval as medical devices (37391665), which puts a barrier between benchmark performance and clinical use that no benchmark can clear.
(b) Method credibility¶
Genome Biology asks readers to stop trusting the direction of a widely used single-cell inference without checking conditions most published applications never check (37885016). The same journal shows that bulk-deconvolution performance depends on experimental factors rather than on the algorithm chosen (37864274), and that pangenome analyses carry irreducible uncertainty from the clustering criterion (37904249). Nucleic Acids Research reports guide-specific efficiency loss across Cas9 variants (37615574) — a reagent, not a pipeline.
Two results push the audit further than the analysis layer. Cell reports chromosome loss in gene-edited T cells manufactured to clinical grade (37794590), which is the same failure mode arriving in a product given to patients and lands on cell-therapy as well. And The Lancet retracts a tissue-engineered airway transplantation paper together with its five-year follow-up (37898523, 37898524) — the original and the durability claim built on it, withdrawn on the same day.
How to read the ratio¶
Thirty-four of this month's sixty-nine cards refute. Across the quarter the refutation share runs near forty per cent, which is higher than the corpus's established rate, and that is a property of how these months were read rather than of the months themselves: the reading brief ranked refutations first and deliberately hunted them. Do not infer that late 2023 was an unusually self-critical period. Two further limits belong on the page rather than in a reader's head. That sentence was written when these months were read from titles alone, and it predicted its own bias correctly: papers that announce their conclusion in the title were over-collected and quieter ones missed. The months were re-scanned from abstracts on 2026-09-04 and the prediction is now measured — 46% of this month's cards state something no title carries, and the month's stance split moved to 34 refutes against 31 supports, so the refutation share held up under the better instrument rather than dissolving. And they were read in arrears, by someone who already knows what followed; the cards are written to what each title supports on its own terms, but that discipline is a choice, not a guarantee.
5. Open items¶
Nothing carried forward.
6. Meetings¶
No abstract book published this month. The abstract layer runs 2023-02 to 2026-08 and is seasonal by nature — meetings are annual, so most months are empty here and that is the expected shape, not a gap in the harvest.
7. Regulatory¶
| Event | Count |
|---|---|
| trial-first-posted | 532 (of which 481 genuinely oncology) |
| fda-approval | 7 |
| ema-authorisation | 2 |
7 FDA actions — dated from each notice's own prose, not the table's posting date, which disagrees on 7 of 190 rows and once by enough to move an approval into the wrong month:
- 2023-10-11 — FDA approves encorafenib with binimetinib for metastatic non-small cell lung cancer with a BRAF V600E mutation
- 2023-10-13 — FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma
- 2023-10-16 — FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer
- 2023-10-20 — FDA expands pediatric indication for entrectinib and approves new pellet formulation
- 2023-10-24 — FDA approves ivosidenib for myelodysplastic syndromes
- 2023-10-27 — FDA approves toripalimab-tpzi for nasopharyngeal carcinoma
- 2023-10-31 — FDA approves pembrolizumab with chemotherapy for biliary tract cancer
1 EMA oncology authorisation:
- 2023-10-30 — Jaypirca
8. Trade press¶
No items. The press archive covers 2024-01 to 2026-08; feeds that cannot be paginated backwards contribute only from the first harvest forward.